152 related articles for article (PubMed ID: 36422579)
1. Glycyrrhizin Interacts with TLR4 and TLR9 to Resolve
Somayajulu M; McClellan SA; Farooq SM; Pitchaikannu A; Xu S; Hazlett L
Pathogens; 2022 Nov; 11(11):. PubMed ID: 36422579
[TBL] [Abstract][Full Text] [Related]
2. Glycyrrhizin Reduces HMGB1 and Bacterial Load in Pseudomonas aeruginosa Keratitis.
Ekanayaka SA; McClellan SA; Barrett RP; Kharotia S; Hazlett LD
Invest Ophthalmol Vis Sci; 2016 Oct; 57(13):5799-5809. PubMed ID: 27792814
[TBL] [Abstract][Full Text] [Related]
3. Topical Glycyrrhizin Is Therapeutic for Pseudomonas aeruginosa Keratitis.
Ekanayaka SA; McClellan SA; Barrett RP; Hazlett LD
J Ocul Pharmacol Ther; 2018 Apr; 34(3):239-249. PubMed ID: 29236588
[TBL] [Abstract][Full Text] [Related]
4. Silencing Toll-like receptor-9 in Pseudomonas aeruginosa keratitis.
Huang X; Barrett RP; McClellan SA; Hazlett LD
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):4209-16. PubMed ID: 16249500
[TBL] [Abstract][Full Text] [Related]
5. HMGB1 Antagonist, Box A, Reduces TLR4, RAGE, and Inflammatory Cytokines in the Cornea of P. aeruginosa-Infected Mice.
Ekanayaka SA; McClellan SA; Peng X; Barrett RP; Francis R; Hazlett LD
J Ocul Pharmacol Ther; 2018 Nov; 34(10):659-69. PubMed ID: 30407111
[TBL] [Abstract][Full Text] [Related]
6. Thrombomodulin Protects Against Bacterial Keratitis, Is Anti-Inflammatory, but Not Angiogenic.
McClellan SA; Ekanayaka SA; Li C; Jiang X; Barrett RP; Hazlett LD
Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):8091-100. PubMed ID: 26720461
[TBL] [Abstract][Full Text] [Related]
7. TLR4 is required for host resistance in Pseudomonas aeruginosa keratitis.
Huang X; Du W; McClellan SA; Barrett RP; Hazlett LD
Invest Ophthalmol Vis Sci; 2006 Nov; 47(11):4910-6. PubMed ID: 17065506
[TBL] [Abstract][Full Text] [Related]
8. Ocular Effects of Glycyrrhizin at Acidic and Neutral pH.
Somayajulu M; McClellan SA; Bessert DA; Pitchaikannu A; Hazlett LD
Front Cell Infect Microbiol; 2021; 11():782063. PubMed ID: 35127554
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Three Ocular Clinical Isolates of P. aeruginosa: Viability, Biofilm Formation, Adherence, Infectivity, and Effects of Glycyrrhizin.
Peng X; Ekanayaka SA; McClellan SA; Barrett RP; Vistisen K; Hazlett LD
Pathogens; 2017 Oct; 6(4):. PubMed ID: 29064403
[TBL] [Abstract][Full Text] [Related]
10. High-mobility group box 1: a novel target for treatment of Pseudomonas aeruginosa keratitis.
McClellan S; Jiang X; Barrett R; Hazlett LD
J Immunol; 2015 Feb; 194(4):1776-87. PubMed ID: 25589066
[TBL] [Abstract][Full Text] [Related]
11. NLRP12 promotes host resistance against Pseudomonas aeruginosa keratitis inflammatory responses through the negative regulation of NF-κB signaling.
Deng QC; Deng CT; Li WS; Shu SW; Zhou MR; Kuang WB
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8063-8075. PubMed ID: 30556841
[TBL] [Abstract][Full Text] [Related]
12. ST2 is essential for Th2 responsiveness and resistance to pseudomonas aeruginosa keratitis.
Huang X; Du W; Barrett RP; Hazlett LD
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4626-33. PubMed ID: 17898286
[TBL] [Abstract][Full Text] [Related]
13. Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection.
Hazlett LD; McClellan SA; Barrett RP; Liu J; Zhang Y; Lighvani S
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):797-807. PubMed ID: 17251480
[TBL] [Abstract][Full Text] [Related]
14. Substance P delays apoptosis, enhancing keratitis after Pseudomonas aeruginosa infection.
Zhou Z; Barrett RP; McClellan SA; Zhang Y; Szliter EA; van Rooijen N; Hazlett LD
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4458-67. PubMed ID: 18566468
[TBL] [Abstract][Full Text] [Related]
15. SIGIRR promotes resistance against Pseudomonas aeruginosa keratitis by down-regulating type-1 immunity and IL-1R1 and TLR4 signaling.
Huang X; Hazlett LD; Du W; Barrett RP
J Immunol; 2006 Jul; 177(1):548-56. PubMed ID: 16785552
[TBL] [Abstract][Full Text] [Related]
16. Effects of Glycyrrhizin Treatment on Diabetic Cornea.
Somayajulu M; McClellan SA; Pitchaikannu A; Bessert D; Liu L; Steinle J; Hazlett LD
J Ocul Pharmacol Ther; 2021; 37(1):12-23. PubMed ID: 33347772
[No Abstract] [Full Text] [Related]
17. Vasoactive intestinal peptide balances pro- and anti-inflammatory cytokines in the Pseudomonas aeruginosa-infected cornea and protects against corneal perforation.
Szliter EA; Lighvani S; Barrett RP; Hazlett LD
J Immunol; 2007 Jan; 178(2):1105-14. PubMed ID: 17202374
[TBL] [Abstract][Full Text] [Related]
18. High-mobility group box1 as an amplifier of immune response and target for treatment in
Wu MQ; Li C; Zhang LN; Lin J; He K; Niu YW; Che CY; Jiang N; Jiang JQ; Zhao GQ
Int J Ophthalmol; 2020; 13(5):708-717. PubMed ID: 32420216
[TBL] [Abstract][Full Text] [Related]
19. MRP8/14 enhances corneal susceptibility to Pseudomonas aeruginosa Infection by amplifying inflammatory responses.
Deng Q; Sun M; Yang K; Zhu M; Chen K; Yuan J; Wu M; Huang X
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1227-34. PubMed ID: 23299480
[TBL] [Abstract][Full Text] [Related]
20. Glycyrrhizin regulates rat TMJOA progression by inhibiting the HMGB1-RAGE/TLR4-NF-κB/AKT pathway.
Hu Z; Xiao M; Cai H; Li W; Fang W; Long X
J Cell Mol Med; 2022 Feb; 26(3):925-936. PubMed ID: 34953035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
